Elicio Therapeutics, Inc. (ELTX) company profile
Close on Nov 17, 2026Market cap $37.58MP/E –Yield –
About Elicio Therapeutics
Pharmaceutical Preparations, SIC 2834
Elicio Therapeutics is a clinical-stage biotechnology company that develops novel cancer immunotherapies, specifically targeting oncogenic drivers such as mutant Kirsten rat sarcoma viral oncogene homolog (mKRAS) in pancreatic, colorectal, and lung cancers. The company utilizes its proprietary Amphiphile platform, which leverages albumin hitchhiking to deliver therapeutic payloads directly to lymph nodes to generate robust, cancer-specific T cell responses. Its clinical pipeline is led by ELI-002, an off-the-shelf lymph-node-targeted peptide immunotherapy evaluated in Phase 1 and Phase 2 trials for mKRAS-driven solid tumors. Its preclinical programs include ELI-007 and ELI-008, targeting mutant BRAF and TP53 driver mutations, respectively, alongside potential platform applications for cellular therapies and auto-immune conditions.
The company engages in clinical and preclinical development through collaborative relationships with academic and medical institutions, including a worldwide patent licensing agreement with the Massachusetts Institute of Technology. The provided text details ongoing multicenter clinical evaluations and partnership opportunities across its immunotherapy pipeline, though it does not state specific facility numbers, operational countries, or the location of its corporate headquarters.
Summary of the business section of Elicio Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Elicio Therapeutics, Inc.
- Headquarters
- Boston, MA
- Address
- 451 D Street, 5th Floor 02210
- Phone
- (857) 209-0050
- Website
- elicio.com
- Employees
- 33, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Baker Tilly US, LLP, Tewksbury, MA
Stock & identifiers
- Ticker
- ELTX
- Former tickers
- ANGN until Jun 2, 2023
- Exchange
- Nasdaq
- IPO date
- Feb 5, 2021
- Shares outstanding
- 26M, Aug 11, 2026
- Public float
- $81.80M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Stock splits
- 1-for-95 reverse, Aug 14, 2023; 1-for-10 reverse, Jun 2, 2023
- SEC CIK
- 1601485
- CUSIP
- 28657F103
- ISIN
- US28657F1030
- FIGI
- BBG00444GM02
- Share class FIGI
- BBG00444GM11
- LEI
- 254900EE2QKYD5SGI956
- EIN
- 11-3430072
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Robert Connelly | CEO, President and Director | 120,570 |
| Peter DeMuth | Chief Scientific Officer | 21,543 |
| Christopher Haqq | See Remarks | 57,381 |
| Preetam Shah | See Remarks | 24,000 |
| Jay Venkatesan | Director | 180,534 |
| Karen J. Wilson | Director | 18,718 |
| Robert R. Ruffolo | Director | – |
| Yekaterina Chudnovsky | Director | 5,416,212 |
| Allen Nissenson | Director | 9,383 |
| Carol Gail Ashe | Director | – |
| Julian Adams | Director | – |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Robert Connelly President, Chief Executive Officer, and Director | $632.70K | $906.96K | $348.00K | – | $1.89M | -7% |
| Preetam Shah Chief Strategy and Financial Officer and Treasurer | $350.61K | $796.14K | $201.60K | $29.33K | $1.38M | – |
| Christopher Haqq Executive Vice President, Head of Research and Development and Chief Medical Officer | $528.10K | $328.18K | $221.90K | – | $1.08M | +16% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Feb 5, 2021
- Offer price
- $16.00
- Securities offered
- 5,000,000
- Gross proceeds
- $80.00M
- Exchange
- Nasdaq
- First trading day
- Feb 5, 2021
- First-day close
- $17.02+6.4%
- Lock-up ends (est.)
- Aug 4, 2021
“The initial public offering price is $16.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 33 employees, all of whom were full-time, 9 of whom have Ph.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jun 2, 2023 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Jun 2, 2023 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| May 30, 2023 | Name change | Name changed from Angion Biomedica Corp. to Elicio Therapeutics, Inc. |
| Feb 13, 2023 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Dec 22, 2022 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Feb 5, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Feb 2, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?